@Arturraposo1R Arturraposo1R
Conviction retail thesis-builder linking macro narratives to undervalued real-economy and health stocks
Posts long-form bullish theses and tickered forward price-ta
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY. · Analyst brief as of 2026-06-22.
Across their last 20 scored bets: 30% hit rate, -0.33% mean alpha, trader score -0.45. Their last-14d mentions, direction-adjusted, have moved +2.7% since posting (mean over 181 mentions with price data).
Author is heavily concentrated in HIMS, disclosing a 50% portfolio allocation while repeatedly pairing HIMS with NVO as GLP-1 and healthcare-platform winners. Distinctive reads are HIMS as misunderstood TAM/platform expansion, OXY/oil as a geopolitical supply-cycle trade, FCX as an AI-buildout copper winner, and NIO as an undervalued China EV/automation setup. Late window shows the strongest incremental conviction around HIMS, plus a mild flip from caution to constructive on SPCX and NIO technicals.
Author’s conviction is most concentrated in HIMS, with repeated bullish technical, TAM, partnership, institutional-accumulation and position-size disclosures culminating in a 50% portfolio allocation. He stays consistently bullish on OXY/oil and FCX/copper while using NVO as a companion GLP-1 healthcare winner. The clearest flips are smaller: SPCX moves from downside warning to bullish, and NIO shifts from technical weakness to support-held accumulation.
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-07-03 | HIMS | @Arturraposo1R | +0.35 | Says GLP-1 penetration is under 10% and likely won't stay that low given trial performance. | — | tweet ↗ |
| 2026-07-03 | NVO | @Arturraposo1R | +0.45 | Says GLP-1 penetration is under 10% and likely won't stay that low given trial performance. | — | tweet ↗ |
| 2026-07-03 | HIMS | @Arturraposo1R | +0.15 | Argues institutions shifted Nike narrative down to buy cheap shares and rerates are coming. | — | tweet ↗ |
| 2026-07-03 | NKE | @Arturraposo1R | +0.55 | Argues institutions shifted Nike narrative down to buy cheap shares and rerates are coming. | — | tweet ↗ |
| 2026-07-03 | ENPH | @Arturraposo1R | +0.60 | Says Cramer's bearishness strengthens ENPH bull thesis and macro/TA agree. | — | tweet ↗ |
| 2026-07-03 | NIO | @Arturraposo1R | +0.45 | Says NIO grows 60% YoY while stock is down, calling the move fabricated and temporary. | — | tweet ↗ |
| 2026-07-03 | NVO | @Arturraposo1R | +0.65 | Discloses they got into NVO around $40 and remain bullish with upside to 200WMA. | — | tweet ↗ |
| 2026-07-03 | REGN | @Arturraposo1R | +0.45 | REGN looks good again with 30% upside to the 200WMA and appears to be value. | — | tweet ↗ |
| 2026-07-03 | HIMS | @Arturraposo1R | +0.50 | Says HIMS, OSCR and NVO are all you need this year. | — | tweet ↗ |
| 2026-07-03 | NVO | @Arturraposo1R | +0.50 | Says HIMS, OSCR and NVO are all you need this year. | — | tweet ↗ |
| 2026-07-03 | OSCR | @Arturraposo1R | +0.50 | Says HIMS, OSCR and NVO are all you need this year. | — | tweet ↗ |
| 2026-07-02 | HIMS | @Arturraposo1R | +0.35 | Mocks bearish reaction to HIMS $400M funding and argues facts beat sentiment. | — | tweet ↗ |
| 2026-07-02 | HIMS | @Arturraposo1R | +0.35 | Portfolio performance post names HIMS and OSCR as ramping quickly. | — | tweet ↗ |
| 2026-07-02 | OSCR | @Arturraposo1R | +0.35 | Portfolio performance post names HIMS and OSCR as ramping quickly. | — | tweet ↗ |
| 2026-07-02 | HIMS | @Arturraposo1R | +0.55 | Calls for healthcare portfolio to outperform Tech and AI until end of 2026. | — | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.